Speaker Profile
M.D., Co-Founder and Chief Medical Officer, Adela
Biography
Dr. Hartman is a leader in oncology diagnostics with over 20 years of experience developing clinical cancer tests. Leveraging her expertise across the continuum of care, from early detection to minimal residual disease monitoring, she has spearheaded pivotal trials in risk stratification, cancer screening, and cancer management during her leadership roles at Myriad Genetics and GRAIL. Driven by a passion for innovation, Dr. Hartman co founded Adela to pioneer a high performing liquid biopsy utilizing whole methylome technology. With diverse expertise in clinical development, product development and diagnostic platforms, she is translating her deep knowledge into transformative molecular approaches for early diagnosis and tailored treatment.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Victor Velculescu, Johns Hopkins University
PMWC Award Ceremony
• Klaus Pantel, University Medical Center Hamburg-Eppendorf / ELBS
• Daniel De Carvalho, University of Toronto
Keynote: Early Detection of Cancer by Multimodal Liquid Biopsy Analysis
• Klaus Pantel, UKE / ELBS
From Mutation to Methylation: The Next Wave of Liquid Biopsy Biomarkers
• Chair: Victor Velculescu, Johns Hopkins University
• Daniel De Carvalho, University of Toronto
• Manel Esteller, Sant Pau Research Institute
• Gordon Sanghera, Oxford Nanopore Technologies
Advancing Minimal Residual Disease Detection Through cfDNA & cfRNA Profiling
• Chair: Luis Diaz, Memorial Sloan Kettering Cancer Center
• Anne-Renee Hartman, Adela
• Klaus Pantel, UKE / ELBS
AI-Informed Biomarker Trials: Turning Early Signals into Actionable Designs
• Chair: Manish Kohli, University of Utah
• Luis Diaz, MSKCC
• Eric Klein, GRAIL
• Peter Bach, DELFI Diagnostics
• Samuel Levy, ClearNote Health
Role of AI in Liquid Biopsies & Cancer Detection
• Chair: Amoolya Singh, DELFI Diagnostics
• Matthew Baker, Dxcover
• Pankaj Vats, NVIDIA
Fragmentomics for Early Detection
• Varsha Rao, Claret Bioscience
Integrating Genetic Risk with Early Detection
• Giordano Botta, Allelica
Metagenomic Diagnostics & Global Pathogen Surveillance
• Charles Chiu, UCSF
AI-Driven Host–Pathogen Signatures from Plasma cfDNA
• Sivan Bercovici, Karius
Ultra-Sensitive Multimodal Liquid Biopsy for Early Cancer Detection
• Atul Sharan, CellMax Life
AI-Enhanced Proteomic Signatures for Early Cancer Detection
• Diana Abdueva, Aqtual
